Skip to main content
Mabpharm Limited logo

Mabpharm Limited — Investor Relations & Filings

Ticker · 2181 ISIN · KYG5780F1046 HKEX Manufacturing
Open in API
Filings indexed 221 across all filing types
Latest filing 2020-12-02 Regulatory Filings
Country HK Hong Kong
Listing HKEX 2181

About Mabpharm Limited

http://www.mabpharm.cn

Mabpharm Limited is a biopharmaceutical company focused on the research, development, production, and commercialization of monoclonal antibody (mAb) drugs and biosimilars. The core therapeutic areas include oncology (cancer) and autoimmune diseases. The company emphasizes bringing high-quality, affordable, and innovative biological drugs to the market by utilizing efficient R&D systems and low-cost manufacturing capabilities. Its robust pipeline features multiple candidates, including 9 monoclonal antibody drugs and 1 strong antibody drug.

Recent filings

Filing Released Lang Actions
RENEWAL OF EXISTING CONTINUING CONNECTED TRANSACTION THE CLINICAL TRIALS AGREEMENT FOR CMAB007
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the renewal of an existing continuing connected transaction related to a clinical trials agreement. It discusses the terms of the Supplemental Clinical Trials Agreement, annual caps, parties involved, and regulatory implications under the Listing Rules. There are no financial statements or detailed financial performance data presented. The document is a formal announcement of a corporate transaction and related regulatory disclosures, not a full financial report or earnings release. It fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement about connected transactions and compliance with listing rules, without constituting an annual report, interim report, or other specific financial filing.
2020-12-02 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2020
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' and details movements in authorized and issued share capital, share options, warrants, convertibles, and other share-related activities for the month ended 31/10/2020. It is addressed to the Hong Kong Exchanges and Clearing Limited, indicating a regulatory filing related to share capital changes. The content focuses on share capital movements, share options, and confirmations related to securities issuance, without financial statements or earnings data. This type of document is a formal regulatory disclosure about share capital changes and share issuance activities, fitting the category of Share Issue/Capital Change announcements rather than a full financial report or earnings release. The document length is substantial (15,000 characters), and it contains detailed data on share capital movements, not merely an announcement of a report. Therefore, the appropriate classification is Share Issue/Capital Change (SHA).
2020-11-04 English
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
Board/Management Information Classification · 95% confidence The document lists the members of the board of directors and their roles, including executive, non-executive, and independent non-executive directors. It also details the composition of the board committees such as the Audit Committee, Remuneration Committee, and Nomination Committee. There is no financial data, no mention of a report or meeting, and no indication of changes in management or director transactions. The content is focused on governance structure and board composition, which fits the category of Board/Management Information (MANG). The document length is short and does not indicate an announcement of a report or voting results, so it is not AGM-R or DVA. Therefore, the best classification is MANG with high confidence.
2020-10-28 English
ANNOUNCEMENT OF (1) CHANGE OF DIRECTOR (2) CHANGE OF CHIEF EXECUTIVE OFFICER AND (3) CHANGE IN COMPOSITION OF BOARD COMMITTEES
Board/Management Information Classification · 100% confidence The document is an announcement from Mabpharm Limited regarding changes in the company's board of directors and senior management positions, including resignation and appointment of executive directors and the chief executive officer. It includes detailed biographical information and terms of service agreements for the new appointees. There is no financial data, earnings information, or report publication mentioned. The content clearly fits the category of announcements about changes in board or management personnel. Therefore, the document is best classified as Board/Management Information (MANG). The document length and detail support a high confidence in this classification.
2020-10-28 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2020
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' and is addressed to the Hong Kong Exchanges and Clearing Limited. It details movements in authorized and issued share capital, share options, warrants, convertibles, and other share-related transactions for the month ended 30/09/2020. The content focuses on share capital changes, share issuance, and confirmations related to securities listing compliance. There are no financial statements, earnings data, management discussion, or audit information. The document is a regulatory filing reporting share capital movements and compliance confirmations to the stock exchange, typical of a Major Shareholding Notification or Share Issue/Capital Change. However, since it reports monthly movements in securities and share capital, it aligns best with Share Issue/Capital Change (SHA) filings, which cover announcements regarding new share issues and capital changes. The document is detailed and substantive, not a brief announcement or a report publication notice. Therefore, the most appropriate classification is SHA with high confidence.
2020-10-07 English
2020 Interim Report
Interim / Quarterly Report Classification · 95% confidence The document contains detailed financial data including interim condensed consolidated statements of profit or loss, financial position, changes in equity, cash flows, and notes to interim condensed consolidated financial information. It also includes management discussion and analysis, an independent review report, and financial highlights for the six months ended June 30, 2020. The presence of interim financial statements and analysis for a period shorter than a full fiscal year indicates this is an Interim / Quarterly Report. The document length is substantial (15,000 characters), and it contains actual financial data, not just an announcement or certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2020-09-22 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.